- Home
- / Aditx Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Aditx Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.6
2024-10-29
Market Capitalization
$3.3 M
2024-10-29
Revenue
$3.2 K
FY, 2025
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 105.0K | 933.7K | 645.2K | 134.0K | 3.2K | |||
| Cost of goods sold | 154.3K | 78.0K | 766.8K | 756.8K | 627.5K | 2.9K | ||
| Gross profit | 27.1K | 166.9K | (111.7K) | (493.5K) | 268.0 | |||
| Gross profit margin, % | 25.8% | 17.9% | -368.3% | 8.4% | ||||
| General and administrative expense | 5.0M | 5.7M | 82.0K | 335.0K | 1.8M | 18.6M | 16.3M | |
| Operating expense total | 5.6M | 5.9M | 1.0M | 42.0M | 25.6M | 26.0M | 27.4M | |
| EBIT | (5.6M) | (5.9M) | (8.9M) | (41.9M) | (25.5M) | (26.1M) | (27.9M) | |
| EBIT margin, % | -39925.1% | -2728.9% | -20796.1% | |||||
| Interest income | 563.0 | 3.1K | 57.3K | 10.2K | 1.5K | |||
| Interest expense | 3.0K | 1.9K | 5.8K | 15.8K | 2.7M | 1.2M | ||
| Pre tax profit | (5.7M) | (5.8M) | (46.4M) | (27.6M) | (32.4M) | (35.0M) | (42.8M) | |
| Net Income | (5.7M) | (5.8M) | (9.3M) | (46.4M) | (27.6M) | (32.4M) | (35.0M) | |
| EPS | (14.9) | (108.0) | (3.1K) | (1.2K) |